Salivary excretion and pharmacokinetics of sulfapyridine after sulfasalazine
- PMID: 21768
- DOI: 10.1002/cpt1977226917
Salivary excretion and pharmacokinetics of sulfapyridine after sulfasalazine
Abstract
The concentrations of sulfapyridine (SP) and N4-acetylsulfapyridine (AcSP) in the plasma and saliva of 5 healthy male adults (3 slow and 2 rapid acetylators) were determined as a function of time after a single 2.0-gm oral dose of sulfasalazine (salicylazosulfapyridine). SP absorption commenced 3.5 to 6 hr after sulfasalazine administration and occurred slowly (apparent absorption t1/2s ranged from 1.6 to 5 hr) irrespective of acetylator phenotype. Appreciable differences existed between slow and rapid acetylators with respect to the biologic t1/2 and total body clearance of SP. SP concentrations in the saliva correlated well with those in the plasma. The saliva:plasma concentration ratio for SP was 0.559 +/- 0.027 (mean of 5 subjects +/- SE) and was dependent of plasma concentration and saliva pH. The mean saliva:plasma concentration ratio for AcSP was lower (0.246 +/- 0.056), consistent with the pH-partition hypothesis, and showed considerably more intrasubject and intersubject variation than the ratio for SP. These findings suggest that measurement of SP concentrations in the saliva may be a convenient, noninvasive method for monitoring indirectly the steady-state plasma (serum) concentrations of SP in patients with ulcerative colitis or Crohn's disease who are receiving sulfasalazine.
Similar articles
-
Saliva: plasma concentration relationships for sulphapyridine following sulphasalazine administration to normal volunteers and patients with inflammatory bowel disease.Br J Clin Pharmacol. 1980 Jan;9(1):91-4. doi: 10.1111/j.1365-2125.1980.tb04802.x. Br J Clin Pharmacol. 1980. PMID: 6101957 Free PMC article. No abstract available.
-
Time course of free and N4-acetylated sulfapyridine concentrations in the plasma and saliva of man after sulfasalazine (salicylazosulfapyridine) administration: preliminary findings.Res Commun Chem Pathol Pharmacol. 1976 Sep;15(1):183-9. Res Commun Chem Pathol Pharmacol. 1976. PMID: 9675
-
Acetylation polymorphism of sulfapyridine in patients with ulcerative colitis and Crohn's disease.Clin Pharmacol Ther. 1975 Nov;18(5 Pt 1):514-20. doi: 10.1002/cpt1975185part1514. Clin Pharmacol Ther. 1975. PMID: 241531
-
Clinical pharmacokinetics of sulphasalazine.Clin Pharmacokinet. 1976 Nov-Dec;1(6):406-25. doi: 10.2165/00003088-197601060-00002. Clin Pharmacokinet. 1976. PMID: 15752 Review.
-
Genetically determined variability in acetylation and oxidation. Therapeutic implications.Drugs. 1985 Apr;29(4):342-75. doi: 10.2165/00003495-198529040-00003. Drugs. 1985. PMID: 2859977 Review.
Cited by
-
The effect of age and acetylator phenotype on the pharmacokinetics of sulfasalazine in patients with rheumatoid arthritis.Clin Pharmacokinet. 1992 Oct;23(4):311-20. doi: 10.2165/00003088-199223040-00006. Clin Pharmacokinet. 1992. PMID: 1356683
-
Saliva: plasma concentration relationships for sulphapyridine following sulphasalazine administration to normal volunteers and patients with inflammatory bowel disease.Br J Clin Pharmacol. 1980 Jan;9(1):91-4. doi: 10.1111/j.1365-2125.1980.tb04802.x. Br J Clin Pharmacol. 1980. PMID: 6101957 Free PMC article. No abstract available.
-
Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.Clin Pharmacokinet. 1985 Jul-Aug;10(4):285-302. doi: 10.2165/00003088-198510040-00001. Clin Pharmacokinet. 1985. PMID: 2864155 Review.
-
Acetylator phenotype and serum levels of sulfapyridine in patients with inflammatory bowel disease.Eur J Clin Pharmacol. 1981;21(3):243-50. doi: 10.1007/BF00627927. Eur J Clin Pharmacol. 1981. PMID: 6119205 No abstract available.
-
Pharmacokinetics of sulfasalazine metabolites in rats following concomitant oral administration of riboflavin.Pharm Res. 1989 Dec;6(12):1067-72. doi: 10.1023/a:1015938706685. Pharm Res. 1989. PMID: 2576130